Wertheimer, Tobias and Dohse, Marius and Afram, Gabriel and Weber, Daniela and Heidenreich, Martin and Holler, Barbara and Kattner, Anna-Sophia and Neubauer, Andreas and Mielke, Stephan and Ljungman, Per and Holler, Ernst and Herr, Wolfgang and Edinger, Matthias and Martinez, Antonio Perez and Fante, Matthias and Wolff, Daniel (2021) Abatacept as salvage therapy in chronic graft-versus-host disease-a retrospective analysis. ANNALS OF HEMATOLOGY, 100 (3). pp. 779-787. ISSN 0939-5555, 1432-0584
Full text not available from this repository. (Request a copy)Abstract
The immunomodulatory fusion protein abatacept has recently been investigated for the treatment of steroid-refractory chronic graft-versus-host disease (cGvHD) in a phase 1 clinical trial. We analyzed the safety and efficacy of abatacept for cGvHD therapy in a retrospective study with 15 patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) and received abatacept for cGvHD with a median age of 49 years. Grading was performed as part of the clinical routine according to the National Institute of Health's (NIH) consensus criteria at initiation of abatacept and 1, 3, 6, 9 and 12 months thereafter. The median time of follow-up was 191 days (range 55-393 days). Best overall response rate (ORR) was 40%. In particular, patients with bronchiolitis obliterans syndrome showed significant clinical improvement and durable responses following abatacept treatment with a response rate of 89% based on improvement in lung severity score (n = 6) or stabilized lung function (n = 4) or both (n = 3). Infectious complications CTCAE degrees III or higher were observed in 3/15 patients. None of the patients relapsed from the underlying malignancy. Thus, abatacept appears to be a promising treatment option for cGvHD, in particular for patients with lung involvement. However, further evaluation within a phase 2 clinical trial is required.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ; Chronic graft-versus-host disease; Abatacept; Salvage therapy; Bronchiolitis obliterans syndrome |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) Medicine > Zentren des Universitätsklinikums Regensburg > Regensburger Centrum für Interventionelle Immunologie (RCI) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 06 Sep 2022 13:09 |
| Last Modified: | 06 Sep 2022 13:09 |
| URI: | https://pred.uni-regensburg.de/id/eprint/46727 |
Actions (login required)
 |
View Item |
